Roeland Nusse (Surrozen)

Sur­rozen re­loads with $50M for fi­nal dash to the clin­ic, shines some light on lead Wnt-mod­u­lat­ing can­di­dates

Two rounds to­talling $83 mil­lion have pro­pelled Sur­rozen through pre­clin­i­cal proof-of-con­cept, cul­mi­nat­ing in two an­ti­body can­di­dates mod­u­lat­ing the Wnt path­way for tis­sue re­gen­er­a­tion. Now, the South San Fran­cis­co biotech is top­ping up $50 mil­lion to com­plete the sprint to the clin­ic.

One of the two IND can­di­dates tar­gets liv­er dis­ease while the oth­er will be ini­tial­ly po­si­tioned for in­flam­ma­to­ry bow­el dis­ease. With the cash in­fu­sion, Sur­rozen can al­so pur­sue more dis­cov­ery projects in dif­fer­ent tis­sues and ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.